EcoR1 Capital EOLS Position
Active4-Fund ConvergenceEcoR1 Capital initiated a new position in Evolus, Inc. (EOLS) in Q4 2025, holding $4.5M worth of shares across 675,000 shares.
EOLS is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 11.9% of float with 5.2 days to cover, indicating significant bearish positioning against EcoR1's long thesis.
About Evolus, Inc.
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Full company profile →Short Interest
11.9%
5.2 days to cover
Frequently Asked Questions
Does EcoR1 Capital own EOLS?
Yes. As of Q4 2025, EcoR1 Capital holds 675,000 shares of Evolus, Inc. (EOLS) valued at $4.5M. This data comes from their SEC 13F filing.
How many hedge funds own EOLS?
4 specialist biotech hedge funds currently hold EOLS, including Perceptive Advisors, Tang Capital Management, Deerfield Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did EcoR1 Capital first buy EOLS?
EcoR1 Capital's position in EOLS was first reported in Q4 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is EcoR1 Capital's EOLS position increasing or decreasing?
EcoR1 Capital initiated a new position in EOLS in the most recent quarter. This is their first reported holding.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
EOLSCompany Page →
All fund holders, insider trades, catalysts, and cash runway
EcoR1 CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →